--- title: "Valneva (VLA) news: offering" url: "https://aibio.space/companies/valneva/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VLA offering news: Valneva registers resale of up to 31,787,634 ordinary shares by selling holders. Valneva SE (EURONEXT: VLA), France." --- VLA Valneva SE EURONEXT · France # Valneva (VLA) news VLA offering news Financings · 2026-06-04 ## [Valneva registers resale of up to 31,787,634 ordinary shares by selling holders](https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/) Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale. ## Latest Valneva news 1. 2026-04-30 Financings [Valneva prices €37 million private placement of shares with attached warrants](https://aibio.space/news/valneva-prices-37-million-private-placement-shares-attached-warrants/) Valneva agreed on April 29, 2026 to sell 15,893,817 new shares, each with a warrant, for €37 million. The warrants could add about €47 million if every one is exercised, at €2.96 each. ## Valneva at a glance - **Ticker**: VLA - **Listing**: EURONEXT - **Country**: France - **Cash, Dec 31, 2025**: €109.7 million ### Related companies - [Valbiotis SA](https://aibio.space/companies/valbiotis/) EURONEXT: ALVAL - [Afyren SA](https://aibio.space/companies/afyren/) EURONEXT: ALAFY - [Transgene SA](https://aibio.space/companies/transgene/) EURONEXT: TNG - [Genfit SA](https://aibio.space/companies/genfit/) EURONEXT: GNFT - [Inventiva SA](https://aibio.space/companies/inventiva/) EURONEXT: IVA - [Euroapi SA](https://aibio.space/companies/euroapi/) EURONEXT: EAPI - [NFL Biosciences SA](https://aibio.space/companies/nfl-biosciences/) EURONEXT: ALNFL - [genOway SA](https://aibio.space/companies/genoway/) EURONEXT: ALGEN ### Also on EURONEXT - [Celyad Oncology SA](https://aibio.space/companies/celyad-oncology/) CYAD - [Valbiotis SA](https://aibio.space/companies/valbiotis/) ALVAL - [Boiron SA](https://aibio.space/companies/boiron/) BOI - [argenx](https://aibio.space/companies/argenx/) ARGX - [Pharming Group NV](https://aibio.space/companies/pharming/) PHARM - [Aelis Farma SA](https://aibio.space/companies/aelis-farma/) AELIS ## What Valneva does Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases. It currently markets three proprietary travel vaccines: IXIARO, DUKORAL and IXCHIQ. IXIARO is indicated for the prevention of Japanese encephalitis in travelers and military personnel, DUKORAL for the prevention of cholera, and IXCHIQ for chikungunya, which is approved under accelerated approval in Europe, Canada, Brazil and the United Kingdom. In January 2026 the company voluntarily withdrew the Biologics License Application and the Investigational New Drug application for IXCHIQ in the United States. Its clinical pipeline includes VLA15, a Phase 3 Lyme disease vaccine candidate developed with Pfizer, which the text describes as the only Lyme vaccine candidate in late-stage trials. The company also has S4V2, a Phase 2 tetravalent bioconjugate candidate against Shigella, developed with LimmaTech Biologics AG, and VLA1601, a Phase 1 Zika vaccine candidate. Valneva has manufacturing facilities across Europe, including BioSafety Level 3 capacity, and its subsidiaries include Valneva Scotland Ltd. and Valneva Sweden AB. The text says it will only consider further development of VLA1601 if concrete private and public funding opportunities materialize. | Product or program | What it is | Stage | |---|---|---| | IXIARO | Vaccine for prevention of Japanese encephalitis in travelers and military personnel | marketed | | DUKORAL | Vaccine for prevention of cholera and travelers' diarrhea in some markets | marketed | | IXCHIQ (VLA1553) | Single-dose live-attenuated vaccine against chikungunya | approved under accelerated approval in Europe, Canada, Brazil and the UK | | VLA15 | Vaccine candidate against Lyme disease, developed with Pfizer | Phase 3 | | S4V2 (Shigella4V2) | Tetravalent bioconjugate vaccine candidate against shigellosis, with LimmaTech | Phase 2 | | VLA1601 | Vaccine candidate against Zika virus | Phase 1 | Summarised from the company's [20-F filed Mar 17, 2026](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/valn-20251231.htm). ## Valneva annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [€174.7 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | [€169.6 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | | Research and development | [€85.3 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | [€74.1 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | | Net income (loss) | [-€115.2 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | [-€12.2 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | | Cash from operations | [-€52.9 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | [-€67.2 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | | Cash and equivalents | [€109.7 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | [€168.3 million](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €109.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Valneva Has Valneva raised money recently? Our latest story on this, dated Jun 4, 2026: "Valneva registers resale of up to 31,787,634 ordinary shares by selling holders". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/). What is the ticker symbol of Valneva? Valneva SE trades under the ticker VLA on EURONEXT. Where is Valneva listed? Valneva SE is listed on EURONEXT. Our directory also records these other listings: BSESOF:AYJ; DUS:AYJ; EUROTLX:4VLA; FWB:AYJ; GETTEX:AYJ; HAM:AYJ; HAN:AYJ; LS:A0MVJZ; LSE:0OB3; LSX:A0MVJZ; MUN:AYJ; NASDAQ:VALN; SWB:AYJ; TRADEGATE:AYJ; VIE:VLA; XETR:AYJ. What is the SEC CIK of Valneva? The SEC Central Index Key (CIK) for Valneva SE is 1836564. Its filings are on SEC EDGAR. How many shares does Valneva have outstanding? 173,539,745 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-17. Which country or territory is Valneva listed under? Our directory records Valneva SE under France. What does Valneva do? Our directory classifies Valneva SE as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Valneva? The ISIN recorded for Valneva SE is FR0004056851. Does aibio.space cover Valneva? aibio.space lists Valneva SE among 2,820 public biotech companies and publishes its news here as stories appear. Where is Valneva incorporated? SEC records list its state or country of incorporation as I0. What does Valneva develop? Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases. It currently markets three proprietary travel vaccines: IXIARO, DUKORAL and IXCHIQ. What is IXIARO from Valneva? IXIARO: Vaccine for prevention of Japanese encephalitis in travelers and military personnel Stage: marketed. What is DUKORAL from Valneva? DUKORAL: Vaccine for prevention of cholera and travelers' diarrhea in some markets Stage: marketed. What is the latest Valneva (VLA) stock news? Our latest story on Valneva, dated Jun 4, 2026: "Valneva registers resale of up to 31,787,634 ordinary shares by selling holders". Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale. [Source](https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/). Is Valneva a smaller reporting company? SEC records list Valneva SE's filer category as: Accelerated filer. ## Investor discussion: Valneva Members talk about Valneva (VLA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Valneva, newest first. Each line links the filing it comes from. 1. 2026-06-04 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1836564/000199937126012100/valneva-f3_060426.htm) 2. 2026-04-30 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1836564/000162828026029000/projectvista6-k.htm) 3. 2025-03-25 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1836564/000199937125003047/valneva-f3_032425.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:VLA on TradingView](https://www.tradingview.com/symbols/EURONEXT-VLA/). ## SEC filings and registration - **SEC name**: Valneva SE - **CIK**: 1836564 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: VALN (Nasdaq) - **State or country of incorporation**: I0 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 6, RUE ALAIN BOMBARD, SAINT-HERBLAIN, France, 44800 - **Phone**: 33 2 28 07 37 10 - **Shares outstanding**: 173,539,745 as of 2025-12-31 (20-F filed 2026-03-17) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026065954/a6-kcoverpagetemplate.htm) filed 2026-10-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026065400/a6-kcoverpagetemplate.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026056999/a6-kcoverpagetemplate.htm) filed 2026-08-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026056525/valn-20260630.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026049149/a6-kcoverpagetemplate.htm) filed 2026-07-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026045398/a6-kcoverpagetemplate.htm) filed 2026-06-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026041033/a6-kcoverpagetemplate.htm) filed 2026-06-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026039308/a6-kcoverpagetemplate.htm) filed 2026-06-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001836564), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Valneva SE is a public biotech or pharmaceutical company listed on EURONEXT under the ticker VLA, recorded under France. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Valneva SE - **Ticker**: VLA - **Listing**: EURONEXT - **Country or territory**: France - **Business scope**: Biotechnology - **ISIN**: FR0004056851 - **Other listed symbols**: BSESOF:AYJ; DUS:AYJ; EUROTLX:4VLA; FWB:AYJ; GETTEX:AYJ; HAM:AYJ; HAN:AYJ; LS:A0MVJZ; LSE:0OB3; LSX:A0MVJZ; MUN:AYJ; NASDAQ:VALN; SWB:AYJ; TRADEGATE:AYJ; VIE:VLA; XETR:AYJ - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/EURONEXT-VLA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/valneva/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Valneva (VLA) news: offering", 2026-10-31, https://aibio.space/companies/valneva/